Navigation Links
ASM Recommends Nasopharyngeal Flocked Swabs as the Specimen of Choice for Influenza A Testing (Including H1N1)
Date:10/27/2009

MURRIETA, Calif., Oct. 27 /PRNewswire/ -- Preparing for this flu season, the American Society for Microbiology (ASM) PSAB Committee on Laboratory Practices has recently published a new interim algorithm providing guidance to clinical laboratories responsible for testing patients with respiratory illness for Influenza A, including H1N1. The document provides a detailed flowchart that guides microbiologists and physicians through patient assessment and differential diagnosis, and provides recommendations for confirmatory testing. The algorithm focuses particular attention on the critical first step, collection of an optimal specimen, because this step determines the sensitivity and accuracy of the diagnosis. The ASM recommends Nasopharyngeal (NP) Flocked Swabs, patented and manufactured by Copan, as the specimen of choice for Influenza testing. In addition to NP Flocked Swabs, NP aspirates, NP washes, or nasal aspirates are also recommended for testing.

Until the introduction of Copan Flocked Swabs, NP aspirates and washes had been the gold standard for specimen collection for respiratory virus diagnostics because traditional fiber swabs are inferior in terms of the amount of patient sample they collect and the ability to transfer that sample into the test platform. Conversely, the aspirate or wash procedure rinses and removes large quantities of patient sample. The widespread endorsement of Flocked Swabs is attributed to the unique design of the applicator which enables improved sample collection and transfer. The success of Flocked Swabs for Influenza testing is due to a combination of a brush-like action that dislodges large numbers of infected cells and capillary hydraulics, which draws liquid sample between the perpendicular fibers. The Flocked Swabs have a unique mechanical and hydrophilic advantage over any other swab technology. Unlike fiber swabs, which absorb well but entrap the sample in a mattress core, and foam swabs, which are hydrophobic and have poor sample uptake, Flocked Swabs collect a large sample volume -- almost four times more than foam swabs -- and then spontaneously release it into any test system.

Endorsement of Copan Nasopharyngeal Flocked Swabs as the specimen of choice for Influenza testing follows the publication of numerous clinical studies that demonstrate equivalent or better test results when compared with NP aspirates or washes. Copan Flocked Swabs are easier to use, cause less patient discomfort and can be used for sample collection at remote centers, whereas NP aspirates and washes must be performed in a hospital setting by trained personnel with material cost that exceeds that of Flocked Swabs. Copan Flocked Swabs are the best swab technology for Influenza testing that equates to the high specimen yields that laboratory professionals are accustomed to with NP aspirates and washes.

About Copan Diagnostics, Inc.

With a reputation for innovation in preanalytics, Copan is the leading manufacturer of collection and transport systems in the world. Copan offers a complete range of microbial sampling products used for traditional culture analysis and molecular diagnostic assays. For more information, visit www.copanusa.com.

SOURCE Copan Diagnostics, Inc.


'/>"/>
SOURCE Copan Diagnostics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. CDC Advisory Committee Recommends Cervarix To Prevent Cervical Cancer in Girls and Young Women
2. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
3. FDA Advisory Panel Recommends Approval of the SEDASYS(R) System
4. HIV/AIDS Research Network Recommends Use of Abbott RealTime Viral Load Test for NIH-Sponsored Clinical Trials
5. FDA Advisory Committee Recommends Approval of Multaq(R) (dronedarone)
6. Task Force Recommends Using Aspirin to Prevent Cardiovascular Disease When the Benefits Outweigh the Harms
7. Independent Data Monitoring Committee Recommends Resuming Enrollment of Non-Squamous NSCLC Patients in the Motesanib MONET1 Trial
8. CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors
9. Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout
10. CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients
11. Task Force Recommends Screening for Hearing Loss in All Newborns
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... , May 17, 2017  Bayer announced today ... portfolio will be presented at the 53 rd ... (ASCO), taking place June 2-6 in Chicago ... at ASCO span prostate, colorectal, liver and thyroid cancers, ... from the Phase II CHRONOS-1 trial of copanlisib in ...
(Date:5/10/2017)... Hologic, Inc. (Nasdaq: HOLX ) announced today ... ended April 1, 2017 .   GAAP diluted earnings ... the prior year period as the sale of the ... non-GAAP diluted EPS of $0.50 increased 6.4%.  Revenue of ... terms.  Excluding the effects of blood screening and the ...
(Date:5/9/2017)... Ind. , May 9, 2017 Zimmer ... leader in musculoskeletal healthcare, today announced it has earned ... Employers of 2017" list. The Company was ranked among ... of Large Employers and Healthcare Equipment and Services. ... employers based on an anonymous, independent survey of over ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... From May 21-23, hearing healthcare professionals gained ... was held at the Marriott Syracuse Downtown Hotel in Syracuse, New York. , ... of independent hearing healthcare providers to help them stay ahead in the industry. At ...
(Date:5/26/2017)... ... May 26, 2017 , ... Mediaplanet is proud to ... campaign in USA Today, which will educate readers on how to take care of ... a large focus is placed on melanoma. Dancing with the Stars professional, Witney Carson, ...
(Date:5/26/2017)... ... May 26, 2017 , ... Leading CEOs ... on May 30th and 31st at The Four Seasons Hotel Boston. , ... the life sciences, offering exclusive access to key decision makers who influence deal ...
(Date:5/26/2017)... ... ... Amir Qureshi, MD is the first physician in Arkansas to implant Nuvecta’s ... Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for chronic ... introduce the most powerful SCS system and the only stretchable lead on the market. ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community ... healthiest seniors are located in the Midwest. With the average cost of healthcare rising ... are concerned with both the quality and affordability of where they live. An annual ...
Breaking Medicine News(10 mins):